The promise for cell and gene therapies (CGTs) to revolutionize cancer therapy is immense, yet unlocking their full potential to treat more diseases and improve patient access will depend on
The field of cell and gene therapy (CGT) is undergoing a significant transformation, with a notable shift towards allogeneic platforms. Placing a spotlight on what has been deemed the ‘future
The possibility of allogeneic “off-the-shelf” engineered T cell therapies as an alternative to overcome the limitations of autologous therapies has long been a goal for the industry, with some of
The Human Leukocyte Antigens (HLA) are surface proteins on our cells and tissues serving as a mechanism for the body to distinguish between self and non-self, so our immune system
The simplicity and speed of immunomagnetic cell separation has made it the go-to method for isolating target cell populations since it was pioneered in 1990 by Miltenyi Biotec. The ability
Women’s History Month is celebrated every year in March to recognize and honor the contributions and achievements of women throughout history. The 2023 National Women’s History theme is “Celebrating Women
Is The Industry Prepared for Another Year of Rapid Growth? The cell and gene therapy (CGT) industry is expected to grow rapidly for the next 10 years with an increasing
The cell therapy market is valued at 15 billion dollars and is set to double in value by 2030. Cell therapy has been instrumental in the development of treatments like
In July of 2022, AllCells was acquired by Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists™. By combining over 30 years of cell and gene therapy (CGT) expertise, our
Unlike classical therapeutics (i.e., monoclonal antibodies), the raw starting materials for cell and gene therapies (CGTs) are derived from patient or donor cells. As such, these sources are not mass-produced
Copyright ©
AllCells. All rights reserved.
